Studying blood and eye scan markers in diabetic macular edema treatment
Compares blood and eye scan markers in people with diabetic macular edema receiving injected treatments.
Plain-language title generated from the registry record
Registry title: Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant
Key facts
- Where
- Mölndal, SwedenSee the 2 sites
Where in Sweden
- Ögonmottagning Mölndal/SUMölndal, SwedenNot yet recruiting
- Sahlgrenska University Hospital, Department of OphthalmologyMölndal, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Vastra Gotaland Region
- Trial code
- NCT06984822
- Record updated
- 21 November 2025
- Original description
This study aims to investigate the association between serum biomarkers and clinical response to anti-VEGF or dexamethasone implant by assessing OCT-biomarkers in patients with diabetic macular edema, DME, and to compare these with a group of naive patients (those not previously treated for DME).Read full original descriptionShow less
Evaluation of Serum and Ocular Coherence Tomography Biomarkers in Patients With Diabetic Macular Edema Treated With Anti-VEGF or Dexamethasone Implant
This study aims to investigate the association between serum biomarkers and clinical response to anti-VEGF or dexamethasone implant by assessing OCT-biomarkers in patients with diabetic macular edema, DME, and to compare these with a group of naive patients (those not previously treated for DME).
Inclusion: Type I or type II DM; DME involving the center of the fovea with CFT more than 280 microns and the presence of intraretinal cysts.
Exclusion: Prior history of any other macular disease; Previous treatment with dexamethasone implants in the last six months for those in the anti-VEGF group; Previous treatment with anti-VEGF in the last two months for those in the dexamethasone implant group; Prior vitreoretinal surgery; Previous laser treatment of the macula; Previous panretinal photocoagulation; Ocular surgery in the previous 3 months.